Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.61 |
| ▸ | MAPK13 | O15264 | 12/20 | 0.61 |
| ▸ | MAPK12 | P53778 | 12/20 | 0.61 |
| ▸ | MAPK11 | Q15759 | 12/20 | 0.61 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | DDR2 | Q16832 | 2/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | CDK8 | P49336 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4504333 | 0.91 | MAPK14 (0.58) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL4080698 | 0.89 | MAPK14 (0.49) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL4078830 | 0.88 | CDK8 (0.59) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL4510455 | 0.82 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL1012719 | 0.81 | MAPK13 (0.78) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL4083113 | 0.80 | MAPK14 (0.61) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL5087248 | 0.80 | MAPK14 (0.68) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL4070541 | 0.78 | ALDH1A1 (0.40) | MAPK14MAPK13MAPK12MAPK11DDR2 | |
| SCHEMBL1012411 | 0.78 | MAPK14 (0.71) | MAPK14MAPK13MAPK12MAPK11JAK2 | |
| SCHEMBL4146349 | 0.78 | MAPK14 (0.44) | MAPK14MAPK13MAPK12MAPK11JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1778686-B9 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2009-07-08 | — | — | EP | disclosed |
| US-7511057-B2 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. (US) | 2009-03-31 | — | — | US | disclosed |
| EP-1778686-B1 | TRIAZOLOPYRIDINYLSULFANYL DERIVATIVES AS P38 MAP KINASE INHIBITORS | PFIZER LTD (GB) | 2008-10-29 | — | — | EP | disclosed |
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | PFIZER INC. | 2006-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060035922-A1 | Triazolopyridinylsulfanyl derivatives as p38 MAP kinase inhibitors | MAPK1, MAPKAPK5, MAPKAPK3 | MAPK14 24/4885MAPK13 23/4885MAPK12 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.